Fondaparinux Sodium
Product Description
BrightGene Bio-Medical Technology Co.,Ltd.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:1000 - 4999
Company types
Specifications
BrightGene Bio-Medical Technology Co.,Ltd.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:1000 - 4999
Company types
More Products from BrightGene Bio-Medical Technology Co.,Ltd. (49)
-
Product FSC
• Status: DMF No.: 028552 • Usage: For Fondaparinux Sodium -
Product Dydrogesterone
• Status: Pilot • Patent Expiration: Off-patent • Usage: Progestogens -
Product Oritavancin
• Status: Pre-validation • Patent Expiration: Off-patent • Usage: Anti-infection -
Product Pimecrolimus
• Status: DMF No.: 030090 • Patent Expiration: Off-patent • Usage: Immunosuppressant -
Product Everolimus（without BHT）
• Status: MF No.: 230MF10023 • Patent Expiration: Off-patent • Usage: Oncology -
Product Midostaurin
• Status: Validated • Patent Expiration: Off-patent • Usage: Oncology -
Product Anidulafungin
Status:
DMF No.: 032010
ASMF Approved
Patent Expiration: Off-patentUsage: Antifungal -
Product Argatroban Monohydrate
• Status: MF No.: 230MF10028; USDMF to be filed in Q4,2020 • Patent Expiration: Off-patent • Usage:Anticoagulant -
Product Caspofungin Acetate
• Status: ASMF Approved & DMF No.:034091 • Patent Expiration:Off-patent • Usage:Antifungal -
Product Entecavir monohydrate
Brightgene Bio-Medical Technology Co.Ltd. Offers a wide range of anti-infective products which includes entecavir monohydrate. It belongs to anti-viral category. Contact us for more information. • Status: DMF No.:031949 • Patent Expiration: Off-patent • Usage:AntiHBV -
Product Eribulin Mesilate
• Status: Validated • Patent Expiration: US：2023.07.20 ；CN：off-patent • Usage: Oncology -
Product Everolimus(2.0% BHT)
• Status: DMF No.:032020 • Patent Expiration: Off-patent • Usage: Oncology